Trimovax0.5 ml

Trimovax is a live attenuated combination vaccine indicated for active immunization against measles, mumps, and rubella.

Established / Guideline-Supported Uses

• Routine childhood immunization: Part of the standard national and WHO Expanded Programme on Immunization (EPI) schedule for the prevention of measles, mumps, and rubella infection in infants and children.
• Catch-up immunization: For children, adolescents, and adults who have not received the recommended two-dose series and who are not known to be immune.
• Susceptible adults: Including women of childbearing age (when not pregnant), healthcare workers, international travelers, and college/institutional entrants without documented immunity or prior vaccination.
• Outbreak control and post-exposure prophylaxis: Administration within 72 hours of measles exposure may prevent or modify disease in susceptible individuals, as guided by public health authorities.

Not Indicated / Off-label Notes

Trimovax is not used to treat active measles, mumps, or rubella infection; it is a preventive (prophylactic) vaccine only. It is not recommended for use outside the age and immune-status criteria established by national immunization guidelines without physician assessment.

Each reconstituted dose (0.5 mL) of Measles, Mumps and Rubella Vaccine [MMR] contains live attenuated measles, mumps, and rubella virus strains grown in appropriate cell culture (e.g., chick embryo cell culture for measles and mumps components, human diploid cell culture for the rubella component), meeting potency requirements established by the manufacturer and regulatory authority. The vaccine also contains stabilizers (e.g., sorbitol, hydrolyzed gelatin), trace amounts of neomycin, and other inactive excipients. Exact strain composition and excipients vary slightly by manufacturer/brand.

Trimovax is a sterile, lyophilized (freeze-dried) preparation of live attenuated measles, mumps, and rubella viruses, supplied together with a diluent for reconstitution. After reconstitution it is a clear yellow liquid administered by subcutaneous injection.

Trimovax works by inducing active immunity that closely mimics natural infection without causing clinical disease in immunocompetent recipients, stimulating the immune system to produce protective antibodies and cell-mediated immunity against all three viruses.

Trimovax belongs to the therapeutic class of live attenuated viral vaccines, specifically a combination vaccine for active immunization against measles, mumps, and rubella.

Mechanism of Action

Measles, Mumps and Rubella Vaccine [MMR] contains live, attenuated (weakened) strains of measles, mumps, and rubella viruses. Following subcutaneous injection, the attenuated viruses replicate locally to a limited extent, which is sufficient to stimulate both humoral (antibody) and cell-mediated immune responses without producing significant clinical illness in an immunocompetent host.

Immunogenicity

A single dose of Measles, Mumps and Rubella Vaccine [MMR] produces seroconversion in approximately 95% or more of recipients for each component; a second dose is given primarily to seroconvert the small percentage of primary vaccine non-responders, boosting overall population immunity to more than 99% for measles. Protective antibody levels are generally long-lasting, and for most recipients are considered to provide lifelong immunity.

Trimovax is administered by subcutaneous injection only, typically into the outer upper arm (older children/adults) or the anterolateral thigh (infants). It must not be given intravenously. The vaccine should be reconstituted immediately before use with the manufacturer-supplied diluent, gently mixed, inspected for particulate matter/discoloration, and used within the time window specified by the manufacturer (typically within 8 hours of reconstitution, stored at 2-8°C and protected from light). Do not administer if the reconstituted vaccine has not been used within this window.

Clinically Significant Interactions

• Antibody-containing blood products (immunoglobulin, whole blood, plasma): Passive antibodies can neutralize the live vaccine viruses and reduce immune response. Trimovax should generally be given either before or with an appropriate interval after such products (commonly 3-11 months, depending on the product and dose), per current immunization guidelines.
• Other live vaccines: Trimovax may be given simultaneously (same day, different sites) with other live virus vaccines (e.g., varicella). If not given on the same day, a minimum interval of 4 weeks between live vaccine doses is recommended to avoid interference with immune response.
• Immunosuppressive therapy (high-dose corticosteroids, chemotherapy, biologic immunosuppressants): Concurrent immunosuppression can impair vaccine response and increase risk of disseminated infection from the live vaccine strains; Trimovax should generally be deferred until immunosuppression has resolved, per physician guidance (see Contraindications).
• Tuberculin skin testing: Trimovax may transiently suppress tuberculin skin test reactivity. Skin testing should be done either on the same day as vaccination or delayed for about 4-6 weeks afterward to avoid a false-negative result.
• Salicylates (aspirin/aspirin-containing products): Some guidance advises caution with salicylate use for several weeks after vaccination because of a theoretical association between wild-type varicella/influenza infection and Reye's syndrome; consult a physician regarding salicylate use in children after live vaccination.

The following side effects have been reported with Trimovax, most of which are mild and self-limiting.

Common (Usually Mild and Self-Limiting)

• Pain, redness, or swelling at the injection site
• Low-grade to moderate fever, typically occurring 5-12 days after vaccination
• Mild measles-like rash, usually appearing 7-14 days post-vaccination
• Transient joint pain/stiffness (arthralgia), more common in adolescent and adult women (rubella component)
• Mild swelling of the parotid or salivary glands (mumps component)
• Irritability, malaise

Less Common / Rare

• Febrile seizures (usually benign, associated with the post-vaccination fever)
• Transient thrombocytopenia (low platelet count)
• Lymphadenopathy
• Rare hypersensitivity reactions, including anaphylaxis (see Contraindications)
• Very rare reports of encephalitis/encephalopathy, far less frequent than with natural measles infection

Pregnancy

Trimovax is contraindicated in pregnancy because it is a live attenuated vaccine with a theoretical risk to the fetus. Women should avoid becoming pregnant for at least 1 month after receiving Trimovax. If a woman is inadvertently vaccinated while pregnant, or becomes pregnant within this window, she should consult her physician; this is not, by itself, an indication for termination of pregnancy, as no confirmed cases of congenital rubella syndrome or vaccine-related fetal harm have been definitively linked to inadvertent vaccination.

Lactation

Trimovax is not considered contraindicated during breastfeeding. Live attenuated rubella virus may occasionally be transmitted in breast milk, but this has not been shown to cause clinically significant disease in infants. Breastfeeding mothers who require vaccination should consult their physician, but breastfeeding itself is not a reason to withhold Trimovax when otherwise indicated.

• Defer for acute illness: Vaccination with Trimovax should be postponed in individuals with moderate or severe acute illness (with or without fever) until recovery.
• Thrombocytopenia: Use with caution in individuals with a history of thrombocytopenia or thrombocytopenic purpura, as Trimovax may rarely cause or exacerbate low platelet counts; weigh benefits and risks with a physician.
• Recent blood products/immunoglobulin: Vaccine efficacy may be reduced if given too soon after receipt of antibody-containing blood products; appropriate spacing is required (see Interactions).
• Family/personal history of seizures: Individuals with a personal or family history of febrile seizures should be monitored, as fever following vaccination can trigger a febrile seizure.
• Egg allergy: Severe egg allergy is not considered a contraindication to Trimovax in current guidance, but individuals with a history of severe allergic reaction should be evaluated by a physician and vaccinated in a setting equipped to manage anaphylaxis.
• Immunocompromised household contacts: Vaccinees should be aware that transmission of vaccine virus is rare, but reasonable hygiene precautions are prudent around severely immunocompromised household members.
• Not for treatment: Trimovax is a preventive vaccine and has no role in treating active measles, mumps, or rubella infection.

True overdose with Trimovax is not a typical clinical concern for a single-dose immunobiological product; however, administration of doses more frequently than recommended, or at a larger volume than indicated, is not advised. If an excessive dose, an inadvertent double dose, or an incorrect route of administration (e.g., accidental intravenous injection) occurs, seek immediate medical attention or contact emergency services/a poison control center, and monitor the individual closely for signs of an allergic or adverse reaction.

Store the lyophilized (unreconstituted) Trimovax vaccine and its diluent in a refrigerator at 2-8°C, protected from light; do not freeze the diluent. After reconstitution, use the vaccine promptly (per the manufacturer's specified window, typically within 8 hours) and keep it refrigerated and protected from light in the interim; discard any unused reconstituted vaccine after this period. Keep out of reach of children.

Pediatric Use

Trimovax is specifically formulated and recommended for routine use in children starting at 12 months of age (with an off-schedule early dose possible from 6 months in specific circumstances such as travel or outbreak response). Safety and efficacy in infants younger than 6 months have not been established, and maternal antibodies may interfere with immune response in very young infants.

Elderly/Adult Use

Trimovax may be given to adults without evidence of immunity (e.g., born after 1957 in some national contexts, healthcare workers, travelers). Routine use in older adults with well-documented prior immunity or natural infection is generally unnecessary.

Immunocompromised Individuals

Contraindicated in individuals with severe immunodeficiency (see Contraindications); may be considered in select individuals with mild/moderate or resolved immunosuppression only after specialist assessment.

Renal/Hepatic Impairment

No specific dose adjustment of Trimovax is established or required for renal or hepatic impairment, as the vaccine is not metabolized through these organ systems in a manner requiring dose modification.

Trimovax is not a continuous treatment but a scheduled immunization course, generally consisting of two doses: the first in early childhood and the second at a later childhood age, given at least 4 weeks apart. Once the complete 2-dose series is administered, no further routine doses are required for most individuals, as protection is considered long-lasting; additional doses may be recommended only in specific outbreak, occupational, or catch-up scenarios per physician or public health guidance.

Trimovax is supplied as a lyophilized (freeze-dried) powder that must be reconstituted with the diluent supplied by the manufacturer immediately before use. Withdraw the entire volume of diluent and inject it into the vial of lyophilized vaccine; gently swirl (do not shake vigorously) until the powder is completely dissolved, producing a clear, yellow solution. Inspect visually for particulate matter or discoloration before use; discard if either is present. Use the reconstituted vaccine within the manufacturer-specified time window (commonly within 8 hours) and discard any unused portion thereafter.

Measles, Mumps and Rubella Vaccine [MMR] is classified as a live attenuated combination viral vaccine, within the broader category of vaccines used for active immunization/immunobiologicals.

Measles, Mumps and Rubella Vaccine [MMR] works by introducing weakened (attenuated) live strains of measles, mumps, and rubella viruses into the body. These attenuated viruses replicate to a limited degree at the injection site and regional lymphoid tissue, triggering the immune system to mount a protective humoral (antibody) and cell-mediated response against each virus, similar to but milder than the response to natural infection, thereby establishing durable protective immunity without causing clinical disease in immunocompetent recipients.

Trimovax is a cornerstone of pediatric preventive care and is recommended as part of routine national and WHO immunization schedules. The first dose is given at 12-15 months of age and the second dose at 4-6 years of age. In special situations (e.g., travel to a measles-endemic area, outbreak response), an early dose may be given to infants 6-11 months old, but this dose does not count toward the routine series and must be followed by the two standard doses at the recommended ages.

Safety and efficacy in infants younger than 6 months have not been established, and Trimovax should not be given to this age group outside specific public-health recommendations. Children with contraindications such as severe immunodeficiency or current moderate/severe illness should have vaccination deferred or avoided, per physician assessment (see Contraindications and Precautions).